Cagrilintide
Cagrilintide is a long-acting amylin analog that makes you feel full through a completely different pathway than GLP-1 drugs. When combined with semaglutide (the CagriSema protocol), it produces significantly more weight loss than either compound alone. Once-weekly dosing for consistent appetite suppression.
About Cagrilintide
Cagrilintide has emerged as a key compound in combinatorial weight management research, particularly in the CagriSema program pairing it with semaglutide. Amylin receptor agonism produces appetite suppression through distinct CNS pathways from GLP-1, suggesting additive or synergistic effects when combined. Phase 2 clinical data demonstrated significant weight reduction with cagrilintide monotherapy, and the combination with semaglutide has shown effects exceeding either agent alone. Research also explores its effects on gastric emptying, glucagon suppression, and postprandial glucose regulation.
Full Research Monograph — 4 PubMed CitationsYou May Also Consider
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
SemaCagri Tre Blend
10mg/10mgThe nuclear option for weight loss — three of the most powerful metabolic compounds combined into one protocol. Hits every appetite and fat-burning pathway known to science.
- Triple-compound weight loss protocol in one preparation
- Combines semaglutide + cagrilintide + retatrutide mechanisms
Retatrutide 12mg
12mgThe most powerful weight loss compound ever studied — triple-receptor agonist that achieved 24% body weight loss in trials, outperforming semaglutide by hitting THREE metabolic pathways.
- Triple-action weight loss — targets GLP-1, GIP, AND glucagon receptors
- 24% body weight loss in trials — MORE than semaglutide